BRIEF published on 06/30/2025 at 14:05, 1 year ago Promising Phase 1b Results for invIOs's APN401 Cell Therapy in Advanced Tumors Cell Therapy Phase 1b Trial InvIOs GmbH APN401 Advanced Tumors
BRIEF published on 06/30/2025 at 14:05, 1 year ago Résultats prometteurs de phase 1b pour la thérapie cellulaire APN401 d'invIOs dans les tumeurs avancées Thérapie Cellulaire InvIOs GmbH APN401 Essai De Phase 1b Tumeurs Avancées
PRESS RELEASE published on 06/30/2025 at 14:00, 1 year ago invIOs reports promising Phase 1b results for cell therapy APN401 in advanced solid tumors invIOs reports successful Phase 1b trial results for APN401 cell therapy in advanced solid tumors, showing safety and efficacy in late-stage cancer patients Solid Tumors Cell Therapy Phase 1b Trial InvIOs APN401
BRIEF published on 12/16/2024 at 15:05, 1 year 6 months ago InvIOs to Highlight Oncology Pipeline Progress at JP Morgan Week 2025 Oncology Cancer Research Cell Therapy Glioblastoma InvIOs GmbH
BRIEF published on 12/16/2024 at 15:05, 1 year 6 months ago InvIOs mettra en avant les progrès du pipeline oncologique lors de la JP Morgan Week 2025 Thérapie Cellulaire Oncologie Glioblastome Recherche Sur Le Cancer InvIOs GmbH
PRESS RELEASE published on 12/16/2024 at 15:00, 1 year 6 months ago invIOs to present progress across oncology pipeline during JP Morgan Week 2025 invIOs GmbH to present progress in oncology pipeline at JP Morgan Week 2025, including updates on glioblastoma treatments INV501 and INV441 in collaboration with DFCI Oncology Pipeline InvIOs GmbH JP Morgan Week 2025 Glioblastoma Treatments DFCI Collaboration
BRIEF published on 10/15/2024 at 10:35, 1 year 8 months ago InvIOs Secures €8.2 Million Series A Funding for Immuno-oncology Innovations Biotechnology Fundraising Clinical Trials Immuno-oncology InvIOs GmbH
BRIEF published on 10/15/2024 at 10:35, 1 year 8 months ago InvIOS obtient un financement de série A de 8,2 millions d'euros pour des innovations en immuno-oncologie Biotechnologie Essais Cliniques Immuno-oncologie Collecte De Fonds InvIOs GmbH
PRESS RELEASE published on 10/15/2024 at 10:30, 1 year 8 months ago invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology invIOs GmbH raises €8.2 million in Series A funding to advance immuno-oncology pipeline progress through 2025, collaborating with Dana-Farber Cancer Institute Series A Funding Immuno-oncology Pipeline Progress InvIOs Dana-Farber Cancer Institute
BRIEF published on 07/17/2024 at 10:05, 1 year 11 months ago InvIOs Selects INV501 Lead Candidate for IND-Enabling Studies in Glioblastoma and Melanoma Cancer Therapy Melanoma Preclinical Studies INV501 Glioblastoma
Published on 07/14/2026 at 01:45, 1 hour 52 minutes ago Arctic Fox Lithium Approved for Trading on the OTCQB Venture Market and Announces DTC Eligibility
Published on 07/14/2026 at 00:01, 3 hours 36 minutes ago Captor Capital Announces Delay in its Annual Filings
Published on 07/13/2026 at 23:10, 4 hours 27 minutes ago Galaxy Ventures Inc. Announces Director Resignation
Published on 07/13/2026 at 21:35, 6 hours 2 minutes ago ATHA Energy Announces Corporate Activities Update
Published on 07/13/2026 at 20:00, 7 hours 37 minutes ago IBC Announces Share-Based Compensation to Directors
Published on 07/13/2026 at 22:30, 5 hours 7 minutes ago Half-year 2026 Results Media and Investor Conference Call and Webcast
Published on 07/13/2026 at 21:20, 6 hours 17 minutes ago Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Published on 07/13/2026 at 21:17, 6 hours 19 minutes ago EQS-Adhoc: Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Published on 07/13/2026 at 20:48, 6 hours 49 minutes ago EQS-Adhoc: Gateway Real Estate AG: Forecast for the financial year 2026
Published on 07/13/2026 at 20:23, 7 hours 14 minutes ago EQS-Adhoc: TRATON SE: Preliminary operating result for Q2 2026 exceeds market expectations
Published on 07/13/2026 at 18:00, 9 hours 37 minutes ago CP Icade - Icade reprend 100% de la propriété de la Tour Eqho à la Défense
Published on 07/13/2026 at 18:00, 9 hours 37 minutes ago PR Icade - Icade regains full ownership of the Eqho Tower in La Défense
Published on 07/13/2026 at 18:00, 9 hours 37 minutes ago THERMADOR GROUPE : publication du chiffre d'affaires semestriel 2026
